Share this article
Share this article
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentzer, Presiden
Date Time
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death called ferroptosis, according to a new study published today in Nature by researchers at The University of Texas MD Anderson Cancer Center. Preclinical findings suggest that targeting DHODH can restore ferroptosis-driven cell death, pointing to new therapeutic strategies that may be used to induce ferroptosis and inhibit tumor growth.
“By understanding ferroptosis and how cells defend against it, we can develop therapeutic strategies to block those defense mechanisms and trigger cell death,” said senior author Boyi Gan, Ph.D., associate professor of Experimental Radiation Oncology. “We have discovered that DHODH plays a key role in defending against ferroptosis and shown that we can exploit this vulnerability with clinically tested
Share this article
Share this article
NAPLES, Fla., May 12, 2021 /PRNewswire/ Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company s Scientific Advisory Board. We believe that Dr. Asher s decision to join Enveric s Scientific Advisory Board gives the Company a significant advantage given his extensive time and expertise at Cedars-Sinai, said David Johnson, Chairman and CEO, Enveric Biosciences. Our mission at Enveric is focused on improving cancer patients quality of life through leveraging the power of cannabinoid medicines. Dr. Asher s deep knowledge of chemotherapy-induced peripheral neuropathy and more should help us achieve this goal of bringing safe, effective care to can
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,.